On demand antimicrobial iodine in a wound contact matrix

伤口接触基质中按需提供抗菌碘

• 批准号: 6534294
• 负责人: BRUCE L GIBBINS
• 金额: $ 51.45万
• 依托单位: ACRYMED, INC.
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-09-15 至 2003-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6534294
• 关键词: antiinfective agents; biomaterial development /preparation; drug delivery systems; drug design /synthesis /production; exudate /transudate; iodine; polyacrylate; slow release drug; topical drug application; wound healing; wound infection

DESCRIPTION (provided by applicant): Wound infection is the single-most important complication encountered in the management of chronic non-healing wounds. More than 10 million US patients per annum, at a cost of greater than $10 billion, receive treatment for chronic wounds. Microorganisms not only interfere with the wound healing process but use open areas as portals of entry for systemic infection. Current clinical strategies rely on the use of topical or systemic antibiotics for controlling wound bioburden. In Phase I we proposed studying the feasibility of incorporating wound exudate responsive chemistry capable of producing elemental iodine directly into a moist wound dressing material. Iodine is antimicrobial at non-toxic levels for tissue but is extremely unstable in its antimicrobial I2 form. Our proposal involved encapsulation of iodine precursors along with conversion chemistry directly into a well known wound contact material. The Phase I results found that signals commonly found in wound exudate fluid triggered the conversion of iodine precursors to antimicrobial elemental iodine. The Phase II studies are aimed at refining the chemistry of the reaction to provide greater control on the rates of production and sustained release of the iodine. Completion of these studies will yield a novel wound sensing antimicrobial dressing for controlling wound bioburden. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

描述（由申请人提供）：伤口感染是最多的 在慢性非治疗的管理中遇到的重要并发症 伤口。每年超过1000万美国患者，费用大于 100亿美元，接受慢性伤口的治疗。微生物不仅是 干扰伤口愈合过程，但使用开放区域作为入口 用于全身感染。当前的临床策略依赖于局部 或用于控制伤口生物负担的全身性抗生素。在第一阶段，我们提出了 研究结合伤口渗出液反应性化学的可行性 能够将元素碘直接产生成潮湿的伤口敷料 材料。碘在组织的无毒水平上是抗菌素，但 其抗菌I2形式极为不稳定。我们的建议涉及 直接封装碘前体以及转化化学 进入众所周知的伤口接触材料。第一阶段结果发现 在伤口渗出液中常见的信号触发了转换 抗菌元素碘的碘前体。第二阶段研究是 旨在完善反应的化学反应，以提供更大的控制 碘的生产率和持续释放。完成 这些研究将产生一种新颖的伤口感应抗菌剂。 控制伤口生物负责。 拟议的商业应用程序：不可用